Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.

[1]  R. Frumento,et al.  Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. , 2003, The Annals of thoracic surgery.

[2]  D. Mangano.  Aspirin and mortality from coronary bypass surgery. , 2002, The New England journal of medicine.

[3]  P. Raven,et al.  Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation , 2002, Perfusion.

[4]  WM Weightmen,et al.  Pharmacological strategies for blood loss , 2001, The Lancet.

[5]  D. Haskard,et al.  Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. , 2000, The Annals of thoracic surgery.

[6]  B. Garayar,et al.  Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery , 2000, Perfusion.

[7]  M. Prins,et al.  Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints , 1999, The Lancet.

[8]  B. Chaitman,et al.  Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. , 1998, The Journal of thoracic and cardiovascular surgery.

[9]  D. Royston.  Aprotinin versus lysine analogues: the debate continues. , 1998, The Annals of thoracic surgery.

[10]  N. Hayashida,et al.  Effects of minimal-dose aprotinin on coronary artery bypass grafting. , 1997, Journal of Thoracic and Cardiovascular Surgery.

[11]  Simon M. Shane,et al.  Meta-analysis, decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in medicine , 1997 .

[12]  J. Copeland,et al.  Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. , 1996, The Annals of thoracic surgery.

[13]  L. Muhlbaier,et al.  Aprotinin: safe and effective only with the full-dose regimen. , 1996, The Annals of thoracic surgery.

[14]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[15]  L. Hedges,et al.  The Handbook of Research Synthesis , 1995 .

[16]  R. E. Clark,et al.  A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. , 1995, Circulation.

[17]  M. Jochum,et al.  Influence of High-dose Aprotinin on Anticoagulation, Heparin Requirement, and Celite- and Kaolin-Activated Clotting Time in Heparin-pretreated Patients Undergoing Open-Heart Surgery: A Double-blind, Placebo-controlled Study , 1995, Anesthesiology.

[18]  R. Hanka.  The Handbook of Research Synthesis , 1994 .

[19]  Diana B. Petitti,et al.  Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .

[20]  G. Guiraudon,et al.  Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[21]  C. Tatooles,et al.  Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. , 1994, The Journal of thoracic and cardiovascular surgery.

[22]  F. Loop,et al.  Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.

[23]  E. Simonson,et al.  The Electrocardiogram in Population Studies: A Classification System , 1960, Circulation.

[24]  J. Fontcuberta,et al.  The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss. , 2000, Haematologica.